FRLN - Freeline Forcefield team up to develop gene therapies for heart diseases

2023-04-04 07:46:33 ET

• Freeline Therapeutics ( NASDAQ: FRLN ) signed a patent and know-how license deal with Forcefield Therapeutics.
• Under the agreement, Freeline gains rights to develop and commercialize AAV gene therapies for certain heart conditions using key targets identified by Forcefield.
• Forcefield will get £500K upfront and is entitled to certain development and regulatory milestone payments plus royalty on net sales.
• The companies said that the agreement centered around the use of gene products identified by FunSel, a genetic 'search engine.' In preclinical AAV gene therapy models, these gene products have shown to minimize damage and preserve heart function after a heart attack.
• "Moving beyond rare diseases to use novel gene therapies to address serious chronic disease is a strategic research priority for Freeline, and this agreement jumpstarts our research efforts to make to help make that vision a reality," said Freeline's CEO Michael Parini.
• FRLN -0.98% to $0.47 premarket April 4

For further details see: